How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Engineered T Cells Market
- By Therapy Type: Chimeric Antigen Receptor T-Cell (CAR-T) Therapy, T-Cell Receptor (TCR) Therapy, Tumor-Infiltrating Lymphocytes (TIL) Therapy, Natural Killer T-Cell (NKT) Therapy
- By Target Indication: Hematologic Malignancies, Solid Tumors, Autoimmune Diseases, Infectious Diseases
- By Cell Source: Autologous T Cells, Allogeneic T Cells
- By End User: Hospitals, Specialty Clinics, Research Institutes
- By Technology Platform: Viral Vector-Based Engineering, Non-Viral Vector-Based Engineering, Gene Editing Technologies (e.g., CRISPR, TALEN)
Top segment
Chimeric Antigen Receptor T-Cell (CAR-T) Therapy XX% share · $X,XXXM
In the full report →
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Chimeric Antigen Receptor T-Cell (CAR-T) Therapy leads By Therapy Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 17 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 289 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.171 →
- 12 Company Profiles 17 players: SWOT & benchmarking p.179 →
Full report · locked preview
Everything inside the Engineered T Cells Market report
A complete, evidence-based study - 12 chapters and 121 sections covering market size, segmentation across 5 axes, regional analysis and 17 company profiles, forecast to 2033.
Segmentation covered
Therapy Type 4
Target Indication 4
Cell Source 2
End User 3
Technology Platform 3
Companies profiled
Novartis AG
Gilead Sciences
Inc. (Kite Pharma)
Bristol-Myers Squibb (Celgene)
Adaptimmune Therapeutics plc
Bluebird Bio Inc.
Legend Biotech Corporation
Celyad Oncology SA
Allogene Therapeutics Inc.
Sorrento Therapeutics Inc.
Poseida Therapeutics Inc.
Autolus Therapeutics plc
+5 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
17 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Gilead Sciences
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Inc. (Kite Pharma)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Bristol-Myers Squibb (Celgene)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Adaptimmune Therapeutics plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Bluebird Bio Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Legend Biotech Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Celyad Oncology SA
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Allogene Therapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Sorrento Therapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Poseida Therapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Autolus Therapeutics plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Tmunity Therapeutics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →Immatics Biotechnologies GmbH
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Caribou Biosciences Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Fate Therapeutics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,822M by 2033 · 5.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Chimeric Antigen Receptor T-Cell (CAR-T) Therapy48.8
- T-Cell Receptor (TCR) Therapy16.5
- Tumor-Infiltrating Lymphocytes (TIL) Therapy17.7
- Natural Killer T-Cell (NKT) Therapy17.0
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$390.9M → $562.7M · 4.7%
Europe$272.4M → $438.2M · 6.1%
Asia Pacific$248.7M → $425.7M · 6.9%
Latin America$154.0M → $219.8M · 4.6%
Middle East and Africa$118.4M → $193.4M · 6.3%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.482026
5.492027
5.502028
5.512029
5.542030
5.552031
5.552032
5.562033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Novartis AG15.8
- Gilead Sciences21.7
- Inc. (Kite Pharma)14.0
- Bristol-Myers Squibb (Celgene)6.0
- Adaptimmune Therapeutics plc5.4
- Bluebird Bio Inc.9.1
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Therapy Type22.0%
Target Indication20.1%
Cell Source22.9%
End User12.9%
Technology Platform22.1%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America30.6
- Europe23.8
- Asia Pacific23.1
- Latin America11.9
- Middle East and Africa10.5
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Novartis AG | 75 | 99 | 94 | 77 | 77 | 74 | 83 |
| Gilead Sciences | 86 | 76 | 78 | 78 | 91 | 87 | 83 |
| Inc. (Kite Pharma) | 69 | 64 | 88 | 88 | 72 | 87 | 78 |
| Bristol-Myers Squibb (Celgene) | 80 | 70 | 58 | 78 | 82 | 71 | 73 |
| Adaptimmune Therapeutics plc | 66 | 75 | 64 | 72 | 63 | 77 | 70 |
| Bluebird Bio Inc. | 53 | 56 | 51 | 65 | 60 | 58 | 57 |
| Legend Biotech Corporation | 48 | 64 | 55 | 44 | 61 | 55 | 55 |
| Celyad Oncology SA | 37 | 59 | 36 | 58 | 39 | 35 | 44 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Novartis AG
- Gilead Sciences
- Inc. (Kite Pharma)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Novartis AG | ✓ | ✓ | ✓ | ✓ | ◐ | ◐ |
| Gilead Sciences | ✓ | ✓ | ✓ | ◐ | ✓ | ✓ |
| Inc. (Kite Pharma) | ✓ | ◐ | ✓ | ✓ | ◐ | ◐ |
| Bristol-Myers Squibb (Celgene) | ◐ | ✓ | ◐ | ✓ | ✓ | ✓ |
| Adaptimmune Therapeutics plc | − | ✓ | ◐ | ◐ | − | ✓ |
| Bluebird Bio Inc. | − | − | − | ◐ | − | − |
| Legend Biotech Corporation | − | ◐ | − | − | ◐ | − |
| Celyad Oncology SA | − | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Novartis AG83
2Gilead Sciences83
3Inc. (Kite Pharma)78
4Bristol-Myers Squibb (Celgene)73
5Adaptimmune Therapeutics plc70
6Bluebird Bio Inc.57
7Legend Biotech Corporation55
8Celyad Oncology SA44
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Novartis AGGilead SciencesInc. (Kite Pharma)
Challenger2
Strong scale, closing on the leaders.
Bristol-Myers Squibb (Celgene)Adaptimmune Therapeutics plc
Contender1
Focused players with pockets of strength.
Bluebird Bio Inc.
Niche2
Specialists in a single segment or region.
Legend Biotech CorporationCelyad Oncology SA
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Therapy Type in North America, then scale across Engineered T Cells Market — a $629M beachhead inside a $10.8B market.
Beachhead (SOM)$629Mobtainable near-term
Serviceable (SAM)$3.94Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
Best fit — highest urgency & budget in Therapy Type.
Economic buyer79 fit
T-Cell Receptor (TCR) Therapy
Strong fit — clear ROI and a fast path to value.
End user68 fit
Tumor-Infiltrating Lymphocytes (TIL) Therapy
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Therapy Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Target Indication & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Cell Source
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel28%
Digital / self-serve22%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Therapy Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Engineered T Cells Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified43%
Sales qualified25%
Evaluation14%
Closed-won7%
$16.0KCAC
$71KLTV
4.5:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Engineered T Cells Market is a resilient opportunity — $2.55B by 2033, compounding at 3.8%.
TAM · 2025$1.89Btoday
TAM · 2033$2.55Bforecast
CAGR3.8%2027–2033
Cumulative$19.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.55BTotal addressable market
SAM$986MServiceable available market
SOM$202MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →3.8% CAGR
Demand compounds through 2033, outpacing GDP across Therapy Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Therapy Type moving from early to mainstream — durable secular demand.
Consolidation upside
17+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.55BLarge & growingTAM by 2033 at 3.8% CAGR
$986MServiceable nowreachable with today’s model
$202MBeachhead winobtainable near-term share
17+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.99BBear2.5% CAGR
$2.55BBase3.8% CAGR
$3.26BBull5.0% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Target Indication optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Engineered T Cells Market — a $1.90B market by 2033. Plan: grow share from 7.1% to 12.7%.
Market size · 2033$1.90Btotal addressable
Market CAGR5.8%2027–2033
Target share12.7%from 7.1% today
Revenue ambition$241Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.1% | 12.7% | Ahead |
| Revenue | $137M | $241M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 36.8% | 40.7% | On track |
| Customer retention | 90.4% | 95.8% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Therapy Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Target Indication capability
A defensible second engine — invest in Target Indication to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Therapy Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Target Indication
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $34M capacity & capability investment
- Greenlight bolt-on M&A in Target Indication
- Authorise North America expansion plan
- Fund R&D program for Therapy Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossBehind
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Engineered T Cells Market conversation — a $2.52B market you can size, segment and defend in minutes.
Market size · 2033$2.52Btotal opportunity
Growth3.7%CAGR to 2033
Addressable buyers1,397+accounts in scope
Typical ROI5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Therapy Type
Goal Grow share in Therapy Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5×return on cost, year one
< 2 mopayback period
$75K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
17+players profiled in this market
Coverage includes
Novartis AGGilead SciencesInc. (Kite Pharma)Bristol-Myers Squibb (Celgene)Adaptimmune Therapeutics plcBluebird Bio Inc.Legend Biotech CorporationCelyad Oncology SA+9 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Engineered T Cells Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Engineered T Cells Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Engineered Cell Therapy Market
Market size, share, segmentation and regional forecast.
$682M market · 2025 base year
View reportCaspofene Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportLow Temperature Superconducting Wires Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportSpunmelt Nonwoven Market
Market size, share, segmentation and regional forecast.
$684M market · 2025 base year
View reportCannabis Extraction Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportTrichloroacetone Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportValeroyl Chloride Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportPsoriasis Treatment Market
Psoriasis Treatment Market is valued at USD 15.74 Billion in 2025 and is expected to reach USD …
$15.7B market · 2025 base year
View reportENG(Endoglin Precursor) Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportEnfuvirtide Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportENFit Syringes Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportENFit Medicine Straws Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.